On January 18, 2023 Chimeric Therapeutics, a clinical stage cell therapy company and an Australian leader in cell therapy, is pleased to reported that the first patient has been dosed in the CHM 0201 (CORE NK) + Vactosertib clinical trial, the first ever trial to assess NK cells in combination with Vactosertib in patients with advanced colorectal and blood cancers (Press release, Chimeric Therapeutics, JAN 18, 2023, View Source [SID1234626334]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
The CHM 0201 (CORE NK) platform is a potential best in class NK cell platform of ex-vivo expanded non HLA-matched universal donor NK cells. The platform was previously studied in a phase 1 clinical trial that established safety with no GvHD (Graft versus Host Disease), 28-day NK cell persistence and an encouraging early efficacy signal, particularly in blood cancers where all patients achieved disease control and one patient achieved a complete response that was sustained for over 15 months at time of study publication.
The objective of this new Phase 1B study is to build upon the clinical responses seen in the initial CORE NK Phase 1A clinical trial by adding Vactosertib, an oral TGF-β receptor inhibitor that can potentially disrupt the TGF-β signaling pathway. This new trial is being led by UH Seidman oncologist J. Eva Selfridge, MD, PhD, and Assistant Professor at Case Western Reserve University School of Medicine in Ohio and is designed to treat 12 patients with either locally advanced/metastatic colorectal cancer or relapsed/refractory blood cancers.
"Both advanced colorectal cancer and acute myeloid leukemia continue to be defined by high unmet needs in the relapse/refractory setting," said Jennifer Chow, Chimeric CEO and Managing Director. "Dosing of the first patient in this trial is a meaningful step towards realizing the potential of CHM 0201 in providing better options for treatment and care to these patients."
The Phase 1B trial is currently funded without financial support from Chimeric Therapeutics.